|
AU759779B2
(en)
*
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
DK1071700T3
(en)
*
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
US7863020B2
(en)
|
2000-06-28 |
2011-01-04 |
Glycofi, Inc. |
Production of sialylated N-glycans in lower eukaryotes
|
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
NZ571596A
(en)
*
|
2001-08-03 |
2010-11-26 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
US7691810B2
(en)
|
2003-10-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Method of producing recombinant antithrombin III composition
|
|
AU2005214382B2
(en)
|
2004-02-19 |
2011-08-04 |
Genentech, Inc. |
CDR-repaired antibodies
|
|
AU2005249566B2
(en)
|
2004-06-04 |
2010-11-11 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
|
BRPI0516297A
(en)
|
2004-10-05 |
2008-09-02 |
Genentech Inc |
Vasculitis treatment methods and articles of manufacture
|
|
JO3000B1
(en)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
Antibody Formulations.
|
|
CN102580084B
(en)
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
The fixed dosage of HER antibody is administered
|
|
EP1850874B1
(en)
|
2005-02-23 |
2013-10-16 |
Genentech, Inc. |
Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
BRPI0619118A2
(en)
|
2005-12-02 |
2011-09-13 |
Genentech Inc |
compositions and methods for the treatment of diseases and disorders associated with cytokine signaling
|
|
BRPI0706840A2
(en)
|
2006-01-05 |
2011-04-05 |
Genentech Inc |
polynucleotide isolated anti-ephb4 antibodies, vector, host cell, method for producing an anti ephb4 antibody, method for producing an anti ephb4 immunoconjugate, method for detecting ephb4, method for diagnosing a composition disorder, method for inhibiting angiogenesis, method for treating a cancer, tumor and / or cell proliferation disorder and use of an antibody
|
|
AR059851A1
(en)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
ANTIBODIES OF EGFL7 AND METHODS OF USE
|
|
EP2032606B1
(en)
|
2006-05-30 |
2013-11-27 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
NZ572177A
(en)
|
2006-06-06 |
2012-02-24 |
Genentech Inc |
Anti-dll4 antibodies and methods using same
|
|
JP2009543579A
(en)
|
2006-07-19 |
2009-12-10 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
WSX-1 / p28 as a target for anti-inflammatory response
|
|
EP3539981A1
(en)
|
2006-09-10 |
2019-09-18 |
Glycotope GmbH |
Use of human cells of myeloid leukaemia origin for expression of antibodies
|
|
BRPI0717638A2
(en)
|
2006-10-27 |
2013-11-12 |
Genentech Inc |
ANTICORPORS AND IMMUNOCUSED AND USES FOR THEM
|
|
PL1920781T3
(en)
|
2006-11-10 |
2015-06-30 |
Glycotope Gmbh |
Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
|
|
MX2009008430A
(en)
|
2007-02-09 |
2009-10-28 |
Genentech Inc |
Anti-robo4 antibodies and uses therefor.
|
|
SI2132573T1
(en)
|
2007-03-02 |
2014-07-31 |
Genentech, Inc. |
Predicting response to a her dimerisation inhbitor based on low her3 expression
|
|
PL2171090T3
(en)
|
2007-06-08 |
2013-09-30 |
Genentech Inc |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
|
KR101680906B1
(en)
|
2007-09-26 |
2016-11-30 |
추가이 세이야쿠 가부시키가이샤 |
Modified antibody constant region
|
|
KR101867606B1
(en)
|
2007-11-07 |
2018-06-18 |
제넨테크, 인크. |
Compositions and methods for treatment of microbial disorders
|
|
TWI468417B
(en)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
Anti-vegf antibodies
|
|
TWI472339B
(en)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
|
|
AR073295A1
(en)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE.
|
|
JP5913980B2
(en)
|
2008-10-14 |
2016-05-11 |
ジェネンテック， インコーポレイテッド |
Immunoglobulin variants and uses thereof
|
|
DK2361085T4
(en)
|
2008-11-22 |
2018-10-08 |
Hoffmann La Roche |
USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
CA2746330C
(en)
|
2008-12-23 |
2017-08-29 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein a
|
|
MY152068A
(en)
|
2009-03-20 |
2014-08-15 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
MA33208B1
(en)
|
2009-03-25 |
2012-04-02 |
Genentech Inc |
ANTI-FGFR3 ANTIBODIES AND METHODS OF USE THEREOF
|
|
NZ594343A
(en)
|
2009-03-25 |
2013-10-25 |
Genentech Inc |
Novel anti-alpha5beta1 antibodies and uses thereof
|
|
SG175077A1
(en)
|
2009-04-07 |
2011-11-28 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US20100316639A1
(en)
|
2009-06-16 |
2010-12-16 |
Genentech, Inc. |
Biomarkers for igf-1r inhibitor therapy
|
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
|
NZ597531A
(en)
|
2009-07-31 |
2014-05-30 |
Genentech Inc |
Inhibition of tumor metastasis using bv8- or g-csf-antagonists
|
|
NZ598131A
(en)
|
2009-08-15 |
2014-08-29 |
Genentech Inc |
Anti-angiogenesis therapy for the treatment of previously treated breast cancer
|
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
RU2559533C2
(en)
|
2009-10-22 |
2015-08-10 |
Дженентек, Инк. |
Anti-hepsin antibodies and methods of application thereof
|
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
|
CA2780221A1
(en)
|
2009-11-04 |
2011-05-12 |
Fabrus Llc |
Methods for affinity maturation-based antibody optimization
|
|
EP2496601B1
(en)
|
2009-11-05 |
2017-06-07 |
F. Hoffmann-La Roche AG |
Methods and composition for secretion of heterologous polypeptides
|
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
|
EP2516465B1
(en)
|
2009-12-23 |
2016-05-18 |
F.Hoffmann-La Roche Ag |
Anti-bv8 antibodies and uses thereof
|
|
KR20130009760A
(en)
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Cd20 antibodies and uses thereof
|
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
|
TWI619509B
(en)
|
2010-02-23 |
2018-04-01 |
建南德克公司 |
Combination of carboplatin, paclitaxel and anti-VEGF antibodies in previously untreated stage III or IV ovarian, fallopian tube or primary peritoneal cancer
|
|
AR080795A1
(en)
|
2010-03-24 |
2012-05-09 |
Genentech Inc |
ANTI-LRP6 ANTIBODIES (PROTEIN RELATED TO THE LDL RECEIVER TYPE 6)
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
|
NZ701208A
(en)
|
2010-06-03 |
2016-05-27 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
|
|
RU2577986C2
(en)
|
2010-06-18 |
2016-03-20 |
Дженентек, Инк. |
Antibodies against axl and their application
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
WO2012006503A1
(en)
|
2010-07-09 |
2012-01-12 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
EP2596026B1
(en)
|
2010-07-23 |
2020-04-08 |
Trustees of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
|
KR20130045914A
(en)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
Chronic lymphocytic leukemia (cll) biomarkers
|
|
JP2013541937A
(en)
|
2010-08-05 |
2013-11-21 |
エフ．ホフマン−ラ ロシュ アーゲー |
Anti-MHC antibody-antiviral cytokine fusion protein
|
|
CA2806021C
(en)
|
2010-08-13 |
2019-05-21 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
|
EP2603529A1
(en)
|
2010-08-13 |
2013-06-19 |
Roche Glycart AG |
Anti-tenascin-c a2 antibodies and methods of use
|
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
|
KR101603001B1
(en)
|
2010-08-25 |
2016-03-11 |
에프. 호프만-라 로슈 아게 |
Antibodies against il-18r1 and uses thereof
|
|
MX2013002084A
(en)
|
2010-08-31 |
2013-05-09 |
Genentech Inc |
BIOMARKERS AND TREATMENT METHODS.
|
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
|
KR20190120439A
(en)
|
2010-11-08 |
2019-10-23 |
제넨테크, 인크. |
Subcutaneously administered anti-il-6 receptor antibody
|
|
WO2012064836A1
(en)
|
2010-11-10 |
2012-05-18 |
Genentech, Inc. |
Methods and compositions for neural disease immunotherapy
|
|
CA2818173C
(en)
|
2010-11-30 |
2022-05-03 |
Genentech, Inc. |
Low affinity blood brain barrier receptor antibodies and uses therefor
|
|
RU2578468C2
(en)
|
2010-12-16 |
2016-03-27 |
Дженентек, Инк. |
Methods for diagnosing and treating related to th2 inhibition
|
|
BR112013014527A2
(en)
|
2010-12-20 |
2017-03-07 |
Genentech Inc |
isolated antibody, isolated nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation, use of immunoconjugate, method for treating an individual who has mesothelin positive cancer, for inhibiting proliferation of a mesothelin positive cell, for detecting human mesothelin in a biological sample and for detecting mesothelin positive cancer
|
|
CN103261230A
(en)
|
2010-12-22 |
2013-08-21 |
霍夫曼-拉罗奇有限公司 |
Anti-PCSK9 antibodies and methods of use
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
AR085404A1
(en)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
PROTEINS OF UNION TO ANTIGEN
|
|
MX342034B
(en)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Monovalent antigen binding proteins.
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
|
US8679767B2
(en)
|
2011-05-12 |
2014-03-25 |
Genentech, Inc. |
Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
|
|
EA030462B1
(en)
|
2011-05-16 |
2018-08-31 |
Дженентек, Инк. |
Fgfr1 agonists and methods of use thereof
|
|
US8623666B2
(en)
|
2011-06-15 |
2014-01-07 |
Hoffmann-La Roche Inc. |
Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
|
|
CN103649125A
(en)
|
2011-06-22 |
2014-03-19 |
霍夫曼-拉罗奇有限公司 |
Clearance of target cells by circulating virus-specific cytotoxic T cells utilizing MHC class I-containing complexes
|
|
AR086823A1
(en)
|
2011-06-30 |
2014-01-22 |
Genentech Inc |
ANTI-C-MET ANTIBODY FORMULATIONS, METHODS
|
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
|
MX2014001766A
(en)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Neuregulin antibodies and uses thereof.
|
|
KR20140068877A
(en)
|
2011-08-17 |
2014-06-09 |
제넨테크, 인크. |
Inhibition of angiogenesis in refractory tumors
|
|
ES2686313T3
(en)
|
2011-08-22 |
2018-10-17 |
Glycotope Gmbh |
Microorganisms that carry a tumor antigen
|
|
RU2014109038A
(en)
|
2011-08-23 |
2015-09-27 |
Рош Гликарт Аг |
ANTIBODIES TO CHONDROITINSULFATE PROTEOGLYCAN MELANOMA
|
|
WO2013040433A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
|
SG11201400724SA
(en)
|
2011-09-19 |
2014-04-28 |
Genentech Inc |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
|
KR101982899B1
(en)
|
2011-09-30 |
2019-05-27 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
Antibodies against tl1a and uses thereof
|
|
SG2014012470A
(en)
*
|
2011-10-05 |
2014-06-27 |
Hoffmann La Roche |
Process for antibody g1 glycoform production
|
|
US9663573B2
(en)
|
2011-10-05 |
2017-05-30 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
|
BR112014008862A2
(en)
|
2011-10-14 |
2018-08-07 |
Genentech Inc |
isolated antibody that binds to htra1, isolated nucleic acid, host cell, immunoconjugate, pharmaceutical formulation, methods and uses
|
|
US9358250B2
(en)
|
2011-10-15 |
2016-06-07 |
Genentech, Inc. |
Methods of using SCD1 antagonists
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
|
AU2012327878A1
(en)
|
2011-10-28 |
2014-05-29 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
|
MX2014004991A
(en)
|
2011-10-28 |
2014-05-22 |
Genentech Inc |
Therapeutic combinations and methods of treating melanoma.
|
|
SG11201402485UA
(en)
|
2011-11-21 |
2014-06-27 |
Genentech Inc |
Purification of anti-c-met antibodies
|
|
WO2013083497A1
(en)
|
2011-12-06 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
|
CN104011080B
(en)
|
2011-12-22 |
2017-10-20 |
弗·哈夫曼-拉罗切有限公司 |
Full-length antibody display system for eukaryotic cells and use thereof
|
|
ES2791758T3
(en)
|
2011-12-22 |
2020-11-05 |
Hoffmann La Roche |
Organization of expression vectors, methods of generating novel production cells and their use for recombinant production of polypeptides
|
|
SG10201900915WA
(en)
|
2011-12-22 |
2019-03-28 |
Hoffmann La Roche |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
|
AR089434A1
(en)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
PROCEDURE TO PREPARE FORMULATIONS WITH HIGH CONCENTRATION OF PROTEINS
|
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
|
CA2863224A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
|
JP2015509091A
(en)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
Humanized antibody
|
|
JP2015506944A
(en)
|
2012-01-18 |
2015-03-05 |
ジェネンテック， インコーポレイテッド |
Methods of using FGF19 modifiers
|
|
US9200072B2
(en)
|
2012-01-18 |
2015-12-01 |
Genentech Inc. |
Anti-LRP5 antibodies and methods of use
|
|
KR102148303B1
(en)
|
2012-02-11 |
2020-08-26 |
제넨테크, 인크. |
R-spondin translocations and methods using the same
|
|
MX360352B
(en)
|
2012-02-15 |
2018-10-30 |
Hoffmann La Roche |
Fc-receptor based affinity chromatography.
|
|
US20130259867A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
AR090549A1
(en)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
ANTI-LGR5 AND IMMUNOCATE PLAYERS
|
|
US9056910B2
(en)
|
2012-05-01 |
2015-06-16 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
EP2849723B1
(en)
|
2012-05-18 |
2018-05-02 |
Genentech, Inc. |
High-concentration monoclonal antibody formulations
|
|
WO2013177062A2
(en)
|
2012-05-21 |
2013-11-28 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
|
RU2625771C2
(en)
|
2012-05-23 |
2017-07-18 |
Дженентек, Инк. |
Therapeutics selection method
|
|
WO2013181575A2
(en)
|
2012-06-01 |
2013-12-05 |
Momenta Pharmaceuticals, Inc. |
Methods related to denosumab
|
|
US20150125848A1
(en)
*
|
2012-06-01 |
2015-05-07 |
Momenta Pharmaceuticals, Inc. |
Methods related to alemtuzumab
|
|
EP2861624A1
(en)
|
2012-06-15 |
2015-04-22 |
F. Hoffmann-La Roche AG |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
RU2684595C2
(en)
|
2012-07-04 |
2019-04-09 |
Ф.Хоффманн-Ля Рош Аг |
Kovalent-related conjuates of antigen-antibody
|
|
DK2869837T3
(en)
|
2012-07-04 |
2016-09-26 |
Hoffmann La Roche |
Anti-theophylline antibodies and methods of use
|
|
EP2870180B1
(en)
|
2012-07-04 |
2024-08-28 |
F. Hoffmann-La Roche AG |
Anti-biotin antibodies and methods of use
|
|
US9803191B2
(en)
|
2012-07-05 |
2017-10-31 |
Genentech, Inc. |
Expression and secretion system
|
|
AR091703A1
(en)
|
2012-07-09 |
2015-02-25 |
Genentech Inc |
ANTIBODIES AND IMMUNOCATE PLAYERS INCLUDING ANTI-CD22 ANTIBODIES
|
|
CN104428007B
(en)
|
2012-07-09 |
2018-03-16 |
基因泰克公司 |
Immunoconjugates comprising anti-CD22 antibody
|
|
IN2014DN10652A
(en)
|
2012-07-09 |
2015-09-11 |
Genentech Inc |
|
|
CN104411337A
(en)
|
2012-07-09 |
2015-03-11 |
基因泰克公司 |
Immunoconjugates comprising anti-cd79b antibodies
|
|
SG11201408538PA
(en)
|
2012-07-13 |
2015-02-27 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
HUE045144T2
(en)
|
2012-08-29 |
2019-12-30 |
Hoffmann La Roche |
Véragygát-shuttle
|
|
US11230589B2
(en)
|
2012-11-05 |
2022-01-25 |
Foundation Medicine, Inc. |
Fusion molecules and uses thereof
|
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
|
MA38165A1
(en)
|
2012-11-08 |
2018-07-31 |
Hoffmann La Roche |
Her3 antigen binding proteins binding to her3 beta hairpin
|
|
CN104968367B
(en)
|
2012-11-13 |
2018-04-13 |
弗·哈夫曼-拉罗切有限公司 |
Antihemagglutinin antibody and application method
|
|
WO2014096015A1
(en)
|
2012-12-21 |
2014-06-26 |
F. Hoffmann-La Roche Ag |
Disulfide-linked multivalent mhc class i comprising multi-function proteins
|
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
WO2014117220A1
(en)
|
2013-02-01 |
2014-08-07 |
Transbio Ltd |
Anti-cd83 antibodies and use thereof
|
|
CN117843785A
(en)
|
2013-02-07 |
2024-04-09 |
Csl有限公司 |
IL-11R binding protein and its application
|
|
JP2016509045A
(en)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
How to treat cancer and prevent drug resistance
|
|
US20140242083A1
(en)
|
2013-02-26 |
2014-08-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
|
MX2015011428A
(en)
|
2013-03-06 |
2016-02-03 |
Genentech Inc |
Methods of treating and preventing cancer drug resistance.
|
|
MX2015010854A
(en)
|
2013-03-14 |
2016-07-20 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use.
|
|
JP6436965B2
(en)
|
2013-03-14 |
2018-12-12 |
ジェネンテック， インコーポレイテッド |
Anti-B7-H4 antibody and immunoconjugate
|
|
JP2016516046A
(en)
|
2013-03-14 |
2016-06-02 |
ジェネンテック， インコーポレイテッド |
Methods for treating cancer and methods for preventing cancer drug resistance
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
WO2014145016A2
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
|
WO2014150877A2
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
CA2905123A1
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
SG11201507427QA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
KR20150131177A
(en)
|
2013-03-15 |
2015-11-24 |
제넨테크, 인크. |
Anti-crth2 antibodies and their use
|
|
BR112015023120A2
(en)
|
2013-03-15 |
2017-11-21 |
Genentech Inc |
method for identifying an individual with a disease or dysfunction, method for predicting the responsiveness of an individual with a disease or dysfunction, method for determining the likelihood that an individual with a disease or dysfunction will exhibit benefit from treatment, method for selecting a therapy, Uses of a pd-11 Axis Binding Antagonist, Assay to Identify an Individual with a Disease, Diagnostic Kit, Method to Evaluate a Treatment Response, and Method to Monitor the Response of a Treated Individual
|
|
UA118028C2
(en)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
|
|
MX364861B
(en)
|
2013-04-29 |
2019-05-09 |
Hoffmann La Roche |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases.
|
|
WO2014177459A2
(en)
|
2013-04-29 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
UA118029C2
(en)
|
2013-04-29 |
2018-11-12 |
Ф. Хоффманн-Ля Рош Аг |
MODIFIED ANTIBODY TO CONTACT HUMAN FCRN AND METHODS OF ITS APPLICATION
|
|
EP3594240B1
(en)
|
2013-05-20 |
2023-12-06 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies and methods of use
|
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
CA2918370A1
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
|
KR102516152B1
(en)
|
2013-08-01 |
2023-03-31 |
파이브 프라임 테라퓨틱스, 인크. |
Afucosylated anti-fgfr2iiib antibodies
|
|
SG11201601044XA
(en)
|
2013-08-12 |
2016-03-30 |
Genentech Inc |
Compositions and method for treating complement-associated conditions
|
|
JP2016537399A
(en)
|
2013-09-17 |
2016-12-01 |
ジェネンテック， インコーポレイテッド |
Method using anti-LGR5 antibody
|
|
CN105813654B
(en)
|
2013-10-11 |
2019-05-31 |
美国政府(由卫生和人类服务部的部长所代表) |
TEM8 antibody and its use
|
|
JP2016537965A
(en)
|
2013-10-11 |
2016-12-08 |
ジェネンテック， インコーポレイテッド |
NSP4 inhibitors and methods of use
|
|
BR112016006929A2
(en)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, HOST CELL, METHODS OF PREPARING ANTIBODY, TREATMENT OF PATIENTS AND GENERATION OF AN ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF THE ANTIBODY
|
|
BR112016008477A2
(en)
|
2013-10-18 |
2017-10-03 |
Genentech Inc |
BODIES, NUCLEIC ACID, HOST CELL, METHOD OF PRODUCING AN ANTIBODY, IMMUNOCONJUGATE, PHARMACEUTICAL FORMULATION AND USES OF THE ANTIBODY
|
|
AR098155A1
(en)
|
2013-10-23 |
2016-05-04 |
Genentech Inc |
METHODS TO DIAGNOSTIC AND TREAT EOSYNOPHYL DISORDERS
|
|
LT3071597T
(en)
|
2013-11-21 |
2020-10-12 |
F. Hoffmann-La Roche Ag |
ANTIBODIES TO ALPHA-SUNUCLEIN AND THEIR USES
|
|
NZ720769A
(en)
|
2013-12-09 |
2022-10-28 |
Allakos Inc |
Anti-siglec-8 antibodies and methods of use thereof
|
|
SG11201604784XA
(en)
|
2013-12-13 |
2016-07-28 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates
|
|
WO2015089375A1
(en)
|
2013-12-13 |
2015-06-18 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
|
WO2015095423A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
IL263466B2
(en)
|
2013-12-17 |
2023-10-01 |
Genentech Inc |
Anti-cd3 antibodies and methods of use
|
|
JP2017507900A
(en)
|
2013-12-17 |
2017-03-23 |
ジェネンテック， インコーポレイテッド |
Method for treating HER2-positive cancer using PD-1 axis binding antagonist and anti-HER2 antibody
|
|
AU2014364593A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
|
|
TWI670283B
(en)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
Antibodies and methods of use
|
|
EP3089758B1
(en)
|
2014-01-03 |
2021-01-27 |
F.Hoffmann-La Roche Ag |
Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
BR112016014945A2
(en)
|
2014-01-03 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
conjugate, pharmaceutical formulation and use
|
|
CN105899540B
(en)
|
2014-01-03 |
2020-02-07 |
豪夫迈·罗氏有限公司 |
Bispecific anti-hapten/anti-blood-brain barrier receptor antibodies, complexes thereof and their use as blood-brain barrier shuttles
|
|
CA2932547C
(en)
|
2014-01-06 |
2023-05-23 |
F. Hoffmann-La Roche Ag |
Monovalent blood brain barrier shuttle modules
|
|
RU2727639C2
(en)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Variants of fc-region with modified ability to bind to fcrn and with preserved ability to bind with protein a
|
|
EP3096797A1
(en)
|
2014-01-24 |
2016-11-30 |
F. Hoffmann-La Roche AG |
Methods of using anti-steap1 antibodies and immunoconjugates
|
|
ES2694857T3
(en)
|
2014-02-04 |
2018-12-27 |
Genentech, Inc. |
Smoothened mutant and methods of using it
|
|
CA2938466C
(en)
|
2014-02-08 |
2021-11-02 |
Genentech, Inc. |
Methods of treating alzheimer's disease
|
|
EP3102230B1
(en)
|
2014-02-08 |
2021-04-28 |
F. Hoffmann-La Roche AG |
Methods of treating alzheimer's disease
|
|
EA201691610A8
(en)
|
2014-02-12 |
2018-05-31 |
Дженентек, Инк. |
ANTI-JAGGED1 ANTIBODIES AND METHODS OF APPLICATION
|
|
UA117608C2
(en)
|
2014-02-21 |
2018-08-27 |
Дженентек, Інк. |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
|
DK3110446T3
(en)
|
2014-02-28 |
2022-02-28 |
Allakos Inc |
Methods and compositions for treating Siglec-8-associated diseases
|
|
AU2015229035B2
(en)
|
2014-03-14 |
2021-08-05 |
Genentech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
CN106103478B
(en)
|
2014-03-21 |
2020-04-03 |
豪夫迈·罗氏有限公司 |
In vitro prediction of antibody half-life in vivo
|
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
RU2016141385A
(en)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
CANCER TREATMENT WITH C-MET ANTAGONISTS AND THEIR CORRELATION WITH HGF EXPRESSION
|
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
|
KR20160146747A
(en)
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
WO2015179658A2
(en)
|
2014-05-22 |
2015-11-26 |
Genentech, Inc. |
Anti-gpc3 antibodies and immunoconjugates
|
|
RU2016144405A
(en)
|
2014-05-23 |
2018-06-26 |
Дженентек, Инк. |
MiT BIOMARKERS AND WAYS OF THEIR APPLICATION
|
|
CN106459202A
(en)
|
2014-06-11 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
Anti-lgR5 antibodies and uses thereof
|
|
CN107073121A
(en)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
Methods of treating and preventing cancer drug resistance
|
|
BR112016029935A2
(en)
|
2014-06-26 |
2017-10-31 |
Hoffmann La Roche |
anti-brdu antibodies, complex, pharmaceutical formulation and antibody use?
|
|
RU2715038C2
(en)
|
2014-07-11 |
2020-02-21 |
Дженентек, Инк. |
Anti-pd-l1 antibodies and methods for their diagnostic use
|
|
CN106488775A
(en)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
NOTCH pathway inhibition
|
|
DK4074735T3
(en)
|
2014-08-28 |
2025-07-14 |
Bioatla Inc |
CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS
|
|
TWI751102B
(en)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
Antibodies and chimeric antigen receptors specific for cd19
|
|
CN114181312A
(en)
*
|
2014-09-10 |
2022-03-15 |
豪夫迈·罗氏有限公司 |
Galactose engineered immunoglobulin 1 antibodies
|
|
WO2016040724A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
MA40579A
(en)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES
|
|
LT3191135T
(en)
|
2014-09-12 |
2020-11-25 |
Genentech, Inc. |
ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES
|
|
MX2017003472A
(en)
|
2014-09-17 |
2017-10-31 |
Genentech Inc |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines.
|
|
HUE049175T2
(en)
|
2014-09-23 |
2020-09-28 |
Hoffmann La Roche |
Method for using anti-CD79b immunoconjugates
|
|
JP2017536102A
(en)
|
2014-10-16 |
2017-12-07 |
ジェネンテック， インコーポレイテッド |
Anti-alpha-synuclein antibodies and methods of use
|
|
EP3209695A4
(en)
|
2014-10-23 |
2018-05-30 |
DendroCyte BioTech Pty Ltd |
Cd83 binding proteins and uses thereof
|
|
US10626176B2
(en)
|
2014-10-31 |
2020-04-21 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind B7-H4
|
|
CA2966523A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
WO2016073380A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
|
CA2960569A1
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-Laroche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
DK3215528T3
(en)
|
2014-11-06 |
2019-10-07 |
Hoffmann La Roche |
Fc region variants with modified FcRn binding and methods of use
|
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
|
CR20170240A
(en)
|
2014-11-10 |
2018-04-03 |
Genentech Inc |
ANTI-INTERLEUCINA-33 ANTIBODIES AND THEIR USES
|
|
CN107105632A
(en)
|
2014-11-10 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
Nephrosis animal model and its therapeutic agent
|
|
EP3224275B1
(en)
|
2014-11-14 |
2020-03-04 |
F.Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer
|
|
WO2016077789A1
(en)
|
2014-11-14 |
2016-05-19 |
The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
SG10201807625PA
(en)
|
2014-11-17 |
2018-10-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
WO2016081640A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
CN107428820B
(en)
|
2014-11-19 |
2022-03-22 |
阿克松神经系统科学公司 |
Humanized tau antibodies in alzheimer's disease
|
|
US10508151B2
(en)
|
2014-11-19 |
2019-12-17 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
JP6859259B2
(en)
|
2014-11-19 |
2021-04-14 |
ジェネンテック， インコーポレイテッド |
Antibodies to BACEl and its use for neurological disease immunotherapy
|
|
EP4141032B1
(en)
|
2014-11-20 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
ES2744540T3
(en)
|
2014-12-05 |
2020-02-25 |
Hoffmann La Roche |
Anti-CD79b antibodies and usage procedures
|
|
KR20170085595A
(en)
|
2014-12-10 |
2017-07-24 |
제넨테크, 인크. |
Blood brain barrier receptor antibodies and methods of use
|
|
KR101860280B1
(en)
|
2014-12-19 |
2018-05-21 |
추가이 세이야쿠 가부시키가이샤 |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
BR112017011235A2
(en)
|
2014-12-19 |
2018-02-06 |
Chugai Pharmaceutical Co Ltd |
anti-c5 antibodies and methods of use
|
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
ES2818103T3
(en)
|
2015-01-16 |
2021-04-09 |
Juno Therapeutics Inc |
ROR1-specific chimeric antigen receptors and antibodies
|
|
CN113956354A
(en)
|
2015-01-22 |
2022-01-21 |
中外制药株式会社 |
Combinations and methods of use of two or more anti-C5 antibodies
|
|
JP2018506275A
(en)
|
2015-01-28 |
2018-03-08 |
ジェネンテック， インコーポレイテッド |
Gene expression markers and treatment of multiple sclerosis
|
|
EP3253784B1
(en)
|
2015-02-04 |
2020-05-06 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
KR102605798B1
(en)
|
2015-02-05 |
2023-11-23 |
추가이 세이야쿠 가부시키가이샤 |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
WO2016138160A1
(en)
|
2015-02-24 |
2016-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
|
MX2017011486A
(en)
|
2015-03-16 |
2018-06-15 |
Genentech Inc |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases.
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
ES2789348T3
(en)
|
2015-03-20 |
2020-10-26 |
Us Health |
Neutralizing antibodies to GP120 and their uses
|
|
PE20171790A1
(en)
|
2015-03-23 |
2017-12-28 |
Bayer Pharma AG |
ANTI-CEACAM6 ANTIBODIES AND THEIR USES
|
|
RS60614B1
(en)
|
2015-03-23 |
2020-08-31 |
Jounce Therapeutics Inc |
Antibodies to icos
|
|
WO2016161390A1
(en)
|
2015-04-03 |
2016-10-06 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
|
CN107810197B
(en)
|
2015-04-24 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
Methods of identifying bacteria comprising binding polypeptides
|
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
|
HK1248577A1
(en)
|
2015-05-11 |
2018-10-19 |
F. Hoffmann-La Roche Ag |
Compositions and methods of treating lupus nephritis
|
|
ES2835866T5
(en)
|
2015-05-12 |
2024-12-02 |
Hoffmann La Roche |
Therapeutic and diagnostic procedures for cancer
|
|
HK1250723A1
(en)
|
2015-05-29 |
2019-01-11 |
F. Hoffmann-La Roche Ag |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
|
ES2789500T5
(en)
|
2015-05-29 |
2023-09-20 |
Hoffmann La Roche |
Therapeutic and diagnostic procedures for cancer
|
|
AR105618A1
(en)
|
2015-05-29 |
2017-10-25 |
Genentech Inc |
METHODATION OF THE PROMOTER OF THE BINDING TO THE PROGRAMMED DEATH RECEIVER (PD-L1) IN CANCER
|
|
HK1249016A1
(en)
|
2015-06-02 |
2018-10-26 |
豪夫迈‧罗氏有限公司 |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
WO2016193497A1
(en)
|
2015-06-04 |
2016-12-08 |
Ospedale San Raffaele Srl |
Inhibitor of igfbp3/tmem219 axis and diabetes
|
|
CN107921094B
(en)
|
2015-06-04 |
2022-03-01 |
圣拉斐尔医院有限公司 |
IGFBP3 and uses thereof
|
|
NZ775762A
(en)
|
2015-06-05 |
2025-02-28 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
|
JP2018521019A
(en)
|
2015-06-08 |
2018-08-02 |
ジェネンテック， インコーポレイテッド |
Method of treating cancer using anti-OX40 antibody
|
|
MX2017015937A
(en)
|
2015-06-08 |
2018-12-11 |
Genentech Inc |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists.
|
|
CN108064246A
(en)
|
2015-06-15 |
2018-05-22 |
基因泰克公司 |
Antibody and immune conjugate
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
|
DK3310814T5
(en)
|
2015-06-16 |
2024-10-07 |
Hoffmann La Roche |
Humanized and affinity matured antibodies against FcRH5 and methods of use
|
|
CN107787331B
(en)
|
2015-06-17 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
anti-HER 2 antibodies and methods of use
|
|
KR102689256B1
(en)
|
2015-06-17 |
2024-07-30 |
제넨테크, 인크. |
Methods for treating locally advanced or metastatic breast cancer using PD-1 axis binding antagonists and taxanes
|
|
US10774145B2
(en)
|
2015-06-17 |
2020-09-15 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
|
HUE057952T2
(en)
|
2015-06-24 |
2022-06-28 |
Hoffmann La Roche |
Anti-transferrin receptor antibodies with customized affinity
|
|
CN107531788B
(en)
|
2015-06-24 |
2022-06-21 |
豪夫迈·罗氏有限公司 |
Trispecific antibodies specific for HER2 and blood brain barrier receptors and methods of use
|
|
EP3978525A1
(en)
|
2015-06-29 |
2022-04-06 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
|
EP3313885A1
(en)
|
2015-06-29 |
2018-05-02 |
H. Hoffnabb-La Roche Ag |
Type ii anti-cd20 antibody for use in organ transplantation
|
|
WO2018028647A1
(en)
|
2016-08-10 |
2018-02-15 |
Legend Biotech Usa Inc. |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
CN105384825B
(en)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
|
|
CN108026180B
(en)
|
2015-08-28 |
2022-06-07 |
豪夫迈·罗氏有限公司 |
Anti-hypusine antibodies and uses thereof
|
|
CA2999369C
(en)
|
2015-09-22 |
2023-11-07 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
|
PE20181363A1
(en)
|
2015-09-23 |
2018-08-27 |
Genentech Inc |
OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES
|
|
JP6955487B2
(en)
|
2015-09-24 |
2021-10-27 |
アブビトロ， エルエルシー |
HIV antibody composition and usage
|
|
PE20181046A1
(en)
|
2015-09-25 |
2018-07-03 |
Genentech Inc |
ANTI-TIGIT ANTIBODIES AND METHODS OF USE
|
|
AR106188A1
(en)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
|
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
CR20180243A
(en)
|
2015-10-02 |
2018-07-31 |
Genentech Inc |
PIRROLOBENZODIAZEPIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
|
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
|
AR106189A1
(en)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
|
|
US10526413B2
(en)
|
2015-10-02 |
2020-01-07 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specific for OX40
|
|
TWI873952B
(en)
|
2015-10-02 |
2025-02-21 |
瑞士商赫孚孟拉羅股份公司 |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
|
IL293708B2
(en)
|
2015-10-06 |
2026-04-01 |
Genentech Inc |
Method for treating multiple sclerosis
|
|
AU2016334623A1
(en)
|
2015-10-07 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies with tetravalency for a costimulatory TNF receptor
|
|
CA2997809A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
|
AU2016342269A1
(en)
|
2015-10-22 |
2018-03-29 |
Jounce Therapeutics, Inc. |
Gene signatures for determining icos expression
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
WO2017072210A1
(en)
|
2015-10-29 |
2017-05-04 |
F. Hoffmann-La Roche Ag |
Anti-variant fc-region antibodies and methods of use
|
|
MY196448A
(en)
|
2015-10-30 |
2023-04-12 |
Genentech Inc |
Anti-Htra1 Antibodies and Methods of use Thereof
|
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
|
WO2017079479A1
(en)
|
2015-11-03 |
2017-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human |
Neutralizing antibodies to hiv-1 gp41 and their use
|
|
CN118725134A
(en)
|
2015-11-08 |
2024-10-01 |
豪夫迈·罗氏有限公司 |
Methods for screening multispecific antibodies
|
|
MX2018006181A
(en)
|
2015-11-23 |
2018-09-24 |
Five Prime Therapeutics Inc |
FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH AGENTS THAT STIMULATE THE IMMUNE SYSTEM IN THE TREATMENT AGAINST CANCER.
|
|
HUE065073T2
(en)
|
2015-12-18 |
2024-04-28 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
|
AR107078A1
(en)
|
2015-12-18 |
2018-03-21 |
Chugai Pharmaceutical Co Ltd |
ANTIMOSTATIN ANTIBODY, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS AS WELL AS METHODS OF USE
|
|
KR20180097615A
(en)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Methods for the treatment of CEA-positive cancers using PD-1 axis-binding antagonists and anti-CEA / anti-CD3 bispecific antibodies
|
|
US20190016791A1
(en)
|
2016-01-20 |
2019-01-17 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
|
EP3411396A1
(en)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
|
JP6821693B2
(en)
|
2016-02-29 |
2021-01-27 |
ジェネンテック， インコーポレイテッド |
Treatment and diagnosis for cancer
|
|
US11767362B1
(en)
|
2016-03-15 |
2023-09-26 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
|
|
CN108700598A
(en)
|
2016-03-25 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
|
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
|
KR20190003958A
(en)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
Treatment and monitoring of cancer
|
|
SMT202600033T1
(en)
|
2016-04-15 |
2026-03-09 |
Bioatla Inc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
|
MX2018012493A
(en)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
METHODS TO CONTROL AND TREAT CANCER.
|
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
|
WO2017191101A1
(en)
|
2016-05-02 |
2017-11-09 |
F. Hoffmann-La Roche Ag |
The contorsbody - a single chain target binder
|
|
JP7089483B2
(en)
|
2016-05-11 |
2022-06-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Modified anti-tenascin antibody and usage
|
|
WO2017194442A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
PL3455261T3
(en)
|
2016-05-13 |
2022-12-12 |
Bioatla, Inc. |
ANTI-ROR2 ANTIBODY, ANTIBODY FRAGMENTS, THEIR IMMUNOCJUGATES AND THEIR APPLICATIONS
|
|
CN118436801A
(en)
|
2016-05-20 |
2024-08-06 |
豪夫迈·罗氏有限公司 |
PROTAC antibody conjugates and methods of use thereof
|
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
KR102376582B1
(en)
|
2016-06-17 |
2022-03-18 |
추가이 세이야쿠 가부시키가이샤 |
Anti-myostatin antibodies and methods of use
|
|
JP7133477B2
(en)
|
2016-06-24 |
2022-09-08 |
ジェネンテック， インコーポレイテッド |
Anti-polyubiquitin multispecific antibody
|
|
WO2018007314A1
(en)
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
US20190185578A1
(en)
|
2016-07-29 |
2019-06-20 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
|
|
JP7062640B2
(en)
|
2016-07-29 |
2022-05-06 |
ジュノー セラピューティクス インコーポレイテッド |
Anti-idiotype antibody against anti-CD19 antibody
|
|
EP3494991A4
(en)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
|
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
|
US11168148B2
(en)
|
2016-09-07 |
2021-11-09 |
The Regents Of The University Of California |
Antibodies to oxidation-specific epitopes
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
CN109689682B
(en)
|
2016-09-19 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
Complement factor-based affinity chromatography
|
|
PT3528838T
(en)
|
2016-09-23 |
2023-09-04 |
Hoffmann La Roche |
Uses of il-13 antagonists for treating atopic dermatitis
|
|
MX2019003768A
(en)
|
2016-10-03 |
2019-06-24 |
Juno Therapeutics Inc |
HPV SPECIFIC BINDING MOLECULES.
|
|
JP7050770B2
(en)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Method for preparing antibody drug conjugate
|
|
CA3038712A1
(en)
|
2016-10-06 |
2018-04-12 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
WO2018081648A2
(en)
|
2016-10-29 |
2018-05-03 |
Genentech, Inc. |
Anti-mic antibidies and methods of use
|
|
HRP20211703T1
(en)
|
2016-11-02 |
2022-02-04 |
Jounce Therapeutics, Inc. |
Antibodies to pd-1 and uses thereof
|
|
JP7784795B2
(en)
|
2016-11-15 |
2025-12-12 |
ジェネンテック， インコーポレイテッド |
Administration for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
JOP20190100A1
(en)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
Anti-gitr antigen-binding proteins and methods of use thereof
|
|
EP4015532A1
(en)
|
2016-11-21 |
2022-06-22 |
cureab GmbH |
Anti-gp73 antibodies and immunoconjugates
|
|
MX2019006330A
(en)
|
2016-12-07 |
2019-09-26 |
Genentech Inc |
Anti-tau antibodies and methods of their use.
|
|
UA128383C2
(en)
|
2016-12-07 |
2024-07-03 |
Дженентек, Інк. |
ANTIBODY TO TAU PROTEIN AND METHOD OF ITS APPLICATION
|
|
EP3551663A1
(en)
|
2016-12-12 |
2019-10-16 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
|
|
AU2017380981B2
(en)
|
2016-12-19 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1BB (CD137) agonists
|
|
KR102692708B1
(en)
|
2016-12-20 |
2024-08-07 |
에프. 호프만-라 로슈 아게 |
Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
|
|
JOP20190134A1
(en)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
Anti-neuropilin antigen-binding proteins and methods of use thereof
|
|
WO2018127473A1
(en)
|
2017-01-03 |
2018-07-12 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
|
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
EP3568468A4
(en)
|
2017-01-12 |
2020-12-30 |
Eureka Therapeutics, Inc. |
AGAINST HISTONE H3 PEPTIDE / MHC COMPLEX CONSTRUCTS AND USES THEREOF
|
|
JP6995127B2
(en)
|
2017-02-10 |
2022-02-04 |
ジェネンテック， インコーポレイテッド |
Anti-tryptase antibody, its composition, and its use
|
|
EP3580235B1
(en)
|
2017-02-10 |
2024-05-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
TW201837467A
(en)
|
2017-03-01 |
2018-10-16 |
美商建南德克公司 |
For the diagnosis and treatment of cancer
|
|
MA49279A
(en)
|
2017-03-22 |
2020-02-05 |
Hoffmann La Roche |
ANTIBODY COMPOSITIONS OPTIMIZED FOR THE TREATMENT OF EYE DISORDERS
|
|
EP3601337A1
(en)
|
2017-03-28 |
2020-02-05 |
Genentech, Inc. |
Methods of treating neurodegenerative diseases
|
|
EP3601346A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
CN110573528B
(en)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
Bispecific antigen-binding molecules targeting co-stimulatory TNF receptors
|
|
JOP20190203A1
(en)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
Anti-tigit antigen-binding proteins and methods of use thereof
|
|
MX2019011769A
(en)
|
2017-04-03 |
2019-11-07 |
Hoffmann La Roche |
Antibodies binding to steap-1.
|
|
JP6997209B2
(en)
|
2017-04-04 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
A novel bispecific antigen-binding molecule capable of specifically binding to CD40 and FAP
|
|
EP4516809A3
(en)
|
2017-04-05 |
2025-09-03 |
F. Hoffmann-La Roche AG |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
KR102294136B1
(en)
|
2017-04-05 |
2021-08-26 |
에프. 호프만-라 로슈 아게 |
anti-LAG3 antibody
|
|
KR20200005540A
(en)
|
2017-04-14 |
2020-01-15 |
제넨테크, 인크. |
How to diagnose and treat cancer
|
|
EP3624820A1
(en)
|
2017-04-21 |
2020-03-25 |
H. Hoffnabb-La Roche Ag |
Use of klk5 antagonists for treatment of a disease
|
|
EP3615574A4
(en)
|
2017-04-26 |
2021-02-24 |
Eureka Therapeutics, Inc. |
CONSTRUCTIONS SPECIFICALLY RECOGNIZING GLYPICANE 3 AND USES OF SUCH LATEST
|
|
SG11201909395TA
(en)
|
2017-04-27 |
2019-11-28 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
EP3618868A4
(en)
|
2017-05-05 |
2021-02-24 |
Allakos Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF ALLERGIC EYE DISEASES
|
|
PT3624837T
(en)
|
2017-05-16 |
2025-10-01 |
Five Prime Therapeutics Inc |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|
|
JP7760242B2
(en)
|
2017-07-21 |
2025-10-27 |
ジェネンテック， インコーポレイテッド |
Cancer treatment and diagnosis methods
|
|
BR112020001653A2
(en)
|
2017-07-26 |
2020-07-21 |
Forty Seven, Inc. |
anti-sirp-alpha antibodies and related methods
|
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
|
JP2020537515A
(en)
|
2017-10-03 |
2020-12-24 |
ジュノー セラピューティクス インコーポレイテッド |
HPV-specific binding molecule
|
|
AU2018347521A1
(en)
|
2017-10-12 |
2020-05-07 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
|
JP2021500902A
(en)
|
2017-11-01 |
2021-01-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
New TNF family ligand trimer-containing antigen-binding molecule
|
|
BR112020007630A2
(en)
|
2017-11-01 |
2020-11-17 |
F. Hoffmann-La Roche Ag |
bispecific ox40 antibody, pharmaceutical product, pharmaceutical composition and bispecific anti-fap / anti-ox40 antibodies
|
|
MY205342A
(en)
|
2017-11-01 |
2024-10-16 |
Hoffmann La Roche |
Bispecific 2+1 contorsbodies
|
|
SG11202003501XA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
|
TW201923089A
(en)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
Diagnostic and therapeutic methods for cancer
|
|
EP4640703A3
(en)
|
2017-11-14 |
2026-04-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibodies and methods of use
|
|
CN111615520A
(en)
|
2017-12-01 |
2020-09-01 |
辉瑞大药厂 |
Anti-CXCR5 antibodies and compositions and uses thereof
|
|
MA51184A
(en)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics Inc |
ANTI-CCT5 BINDING MOLECULES AND RELATED METHODS OF USE
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
MX2020006119A
(en)
|
2017-12-21 |
2020-08-24 |
Hoffmann La Roche |
Antibodies binding to hla-a2/wt1.
|
|
EA202091540A1
(en)
|
2017-12-22 |
2021-03-22 |
Джаунс Терапьютикс, Инк. |
ANTIBODIES TO LILRB2
|
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
|
CN117050184A
(en)
|
2017-12-28 |
2023-11-14 |
南京传奇生物科技有限公司 |
Single domain antibodies to TIGIT and variants thereof
|
|
EP3732203A4
(en)
|
2017-12-28 |
2021-12-15 |
Nanjing Legend Biotech Co., Ltd. |
ANTIBODIES AND VARIANTS THEREOF AGAINST PD-L1
|
|
EP3731864A1
(en)
|
2017-12-29 |
2020-11-04 |
F. Hoffmann-La Roche SA |
Anti-vegf antibodies and methods of use
|
|
EP3724223A1
(en)
|
2018-01-02 |
2020-10-21 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
MX2020007077A
(en)
|
2018-01-04 |
2020-10-28 |
Iconic Therapeutics Inc |
ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY-DRUG CONJUGATES AND RELATED METHODS.
|
|
AU2019205090A1
(en)
|
2018-01-05 |
2020-08-06 |
Ac Immune Sa |
Misfolded TDP-43 binding molecules
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
CN111699200B
(en)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
Single domain antibodies against PD-1 and variants thereof
|
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
|
CN112020365A
(en)
|
2018-01-26 |
2020-12-01 |
豪夫迈·罗氏有限公司 |
Composition and method of use
|
|
CR20200327A
(en)
|
2018-01-26 |
2020-11-05 |
Genentech Inc |
Il-22 fc fusion proteins and methods of use
|
|
US11807663B2
(en)
|
2018-02-01 |
2023-11-07 |
Innovent Biologics (Suzhou) Co., Ltd. |
Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof
|
|
IL325995A
(en)
|
2018-02-08 |
2026-03-01 |
Genentech Inc |
Bispecific antigen-binding molecules and methods of use
|
|
TWI829667B
(en)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
Antibodies binding to gprc5d
|
|
KR20220098056A
(en)
|
2018-02-09 |
2022-07-08 |
제넨테크, 인크. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
|
JP7350756B2
(en)
|
2018-02-14 |
2023-09-26 |
アバ セラピューティクス アーゲー |
Anti-human PD-L2 antibody
|
|
KR20200123118A
(en)
|
2018-02-21 |
2020-10-28 |
제넨테크, 인크. |
Dosing for treatment with IL-22 Fc fusion protein
|
|
RU2020130795A
(en)
|
2018-02-21 |
2022-03-21 |
Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз |
NEUTRALIZING ANTIBODIES TO ENV HIV-1 AND THEIR USE
|
|
CN111836831A
(en)
|
2018-02-26 |
2020-10-27 |
豪夫迈·罗氏有限公司 |
Administration for Anti-TIGIT Antagonist Antibody and Anti-PD-L1 Antagonist Antibody Therapy
|
|
EP3765489B1
(en)
|
2018-03-13 |
2024-10-16 |
F. Hoffmann-La Roche AG |
Therapeutic combination of 4-1bb agonists with anti-cd20 antibodies
|
|
TWI841551B
(en)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
Combination therapy with targeted 4-1bb (cd137) agonists
|
|
EP3765522A4
(en)
|
2018-03-14 |
2022-05-18 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
ANTI-CLAUDIN ANTIBODIES 18.2
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CN112119090B
(en)
|
2018-03-15 |
2023-01-13 |
中外制药株式会社 |
Anti-dengue virus antibodies cross-reactive to Zika virus and methods of use
|
|
BR112020019083A2
(en)
|
2018-03-21 |
2020-12-29 |
Five Prime Therapeutics, Inc. |
ANTIBODIES, NUCLEIC ACID, COMPOSITIONS, CELL AND METHODS FOR PREPARING AN ANTIBODY, FOR TREATING CANCER, FOR TREATING AN INFECTIOUS DISEASE, FOR TREATING INFLAMMATION, FOR THE IDENTIFICATION OF AN ANTIBODY, TO IMPROVE THE ANTICORUS OF ANTICORUS AND ANTICORUS OF AN ANTIBODY, TO SELECT AN ANTIBODY, TO IMPROVE ANTIBODY EFFICIENCY, TO ISOLATE ANTIBODIES, TO DETECT VIEW IN A SAMPLE AND TO TREAT CANCER
|
|
JP2021519073A
(en)
|
2018-03-29 |
2021-08-10 |
ジェネンテック， インコーポレイテッド |
Regulation of lactogenic activity in mammalian cells
|
|
TW202003567A
(en)
|
2018-03-30 |
2020-01-16 |
大陸商南京傳奇生物科技有限公司 |
Single-domain antibodies against LAG-3 and uses thereof
|
|
TW202011029A
(en)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
Methods for detecting and quantifying FGF21
|
|
EP3773908A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
|
SG11202007961QA
(en)
|
2018-04-13 |
2020-09-29 |
Hoffmann La Roche |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
|
WO2019222296A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
SG11202010496WA
(en)
|
2018-05-18 |
2020-12-30 |
Daiichi Sankyo Co Ltd |
Anti-muc1 antibody-drug conjugate
|
|
EP3818085A4
(en)
|
2018-06-01 |
2022-03-09 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
COMPOSITIONS AND THEIR USES FOR TREATING A DISEASE OR CONDITION
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
WO2019235426A1
(en)
|
2018-06-04 |
2019-12-12 |
中外製薬株式会社 |
Antigen-binding molecule showing changed half-life in cytoplasm
|
|
TWI851577B
(en)
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
Camptothecin conjugates
|
|
US11993661B2
(en)
|
2018-06-18 |
2024-05-28 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
|
|
MY205645A
(en)
|
2018-06-23 |
2024-11-02 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
WO2020007817A1
(en)
|
2018-07-04 |
2020-01-09 |
F. Hoffmann-La Roche Ag |
Novel bispecific agonistic 4-1bb antigen binding molecules
|
|
CN113056483B
(en)
|
2018-07-09 |
2025-08-01 |
戊瑞治疗有限公司 |
Antibodies that bind to ILT4
|
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
PE20210687A1
(en)
|
2018-07-11 |
2021-04-08 |
Bristol Myers Squibb Co |
ANTIBODIES FROM BINDING TO SIGHT TO ACID PH
|
|
WO2020018789A1
(en)
|
2018-07-18 |
2020-01-23 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
|
MX2021000745A
(en)
|
2018-07-20 |
2021-03-26 |
Surface Oncology Inc |
Anti-cd112r compositions and methods.
|
|
MX2021000827A
(en)
|
2018-08-03 |
2021-03-25 |
Chugai Pharmaceutical Co Ltd |
ANTIGEN-BINDING MOLECULE CONTAINING TWO ANTIGEN-BINDING DOMAINS THAT ARE LINKED TO EACH OTHER.
|
|
MA50586A
(en)
|
2018-08-09 |
2020-09-16 |
Regeneron Pharma |
METHODS FOR EVALUATING THE BINDING AFFINITY OF AN ANTIBODY VARIANT TO THE NEONATAL FC RECEPTOR
|
|
KR102259473B1
(en)
|
2018-08-10 |
2021-06-02 |
추가이 세이야쿠 가부시키가이샤 |
Anti-CD137 antigen binding molecules and uses thereof
|
|
CN121248772A
(en)
|
2018-08-17 |
2026-01-02 |
Ab工作室有限公司 |
Catalytic antibodies and their usage
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
EP3850013A4
(en)
|
2018-09-10 |
2022-10-05 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND THEIR CONSTRUCTS
|
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
KR102739487B1
(en)
|
2018-09-21 |
2024-12-10 |
제넨테크, 인크. |
Diagnostic methods for triple-negative breast cancer
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
WO2020070041A1
(en)
|
2018-10-01 |
2020-04-09 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-fap clone 212
|
|
CN112654641A
(en)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
Bispecific antigen binding molecules with trivalent binding to CD40
|
|
EP3632929A1
(en)
|
2018-10-02 |
2020-04-08 |
Ospedale San Raffaele S.r.l. |
Antibodies and uses thereof
|
|
PE20211213A1
(en)
|
2018-10-05 |
2021-07-05 |
Five Prime Therapeutics Inc |
ANTI-FGFR2 ANTIBODY FORMULATIONS
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
CA3117856A1
(en)
|
2018-10-31 |
2020-05-07 |
Bayer Aktiengesellschaft |
Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
|
|
CN113366022B
(en)
|
2018-11-16 |
2025-11-21 |
纪念斯隆凯特琳癌症中心 |
Antibodies to mucin-16 and methods of use thereof
|
|
CN116003597A
(en)
|
2018-11-27 |
2023-04-25 |
舒泰神（北京）生物制药股份有限公司 |
Antibody specifically recognizing granulocyte-macrophage colony-stimulating factor receptor alpha and use thereof
|
|
EP4198057A1
(en)
|
2018-12-05 |
2023-06-21 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for cancer immunotherapy
|
|
BR112021010908A2
(en)
|
2018-12-06 |
2021-08-31 |
Genentech, Inc. |
METHOD FOR TREATMENT OF DIFFUSED LARGE B-CELL LYMPHOMA, KIT AND IMMUNOCONJUGATE
|
|
JP2022513198A
(en)
|
2018-12-10 |
2022-02-07 |
ジェネンテック， インコーポレイテッド |
Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins
|
|
US20220089694A1
(en)
|
2018-12-20 |
2022-03-24 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
|
AR117453A1
(en)
|
2018-12-20 |
2021-08-04 |
Genentech Inc |
CF OF MODIFIED ANTIBODIES AND METHODS TO USE THEM
|
|
EP3898671A1
(en)
|
2018-12-21 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Antibody that binds to vegf and il-1beta and methods of use
|
|
CR20210330A
(en)
|
2018-12-21 |
2021-07-20 |
Hoffmann La Roche |
ANTIBODIES JOINING CD3 (Divisional 2021-0325)
|
|
UA128001C2
(en)
|
2018-12-21 |
2024-03-06 |
Ф. Хоффманн-Ля Рош Аг |
TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES
|
|
WO2020127628A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
|
CA3122773A1
(en)
|
2018-12-26 |
2020-07-02 |
Xilio Development, Inc. |
Anti-ctla4 antibodies and methods of use thereof
|
|
EP3902830A1
(en)
|
2018-12-30 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Anti-rabbit cd19 antibodies and methods of use
|
|
AU2020208193A1
(en)
|
2019-01-14 |
2021-07-29 |
BioNTech SE |
Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
|
|
US20220128561A1
(en)
|
2019-01-17 |
2022-04-28 |
Bayer Aktiengesellschaft |
Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc)
|
|
CN113795511B
(en)
|
2019-01-23 |
2024-07-23 |
大有华夏生物医药集团有限公司 |
Anti-PD-L1 double antibody and its use
|
|
WO2020153467A1
(en)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
Novel cancer antigens and antibodies of said antigens
|
|
SG11202107976SA
(en)
|
2019-01-29 |
2021-08-30 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
CN119039441A
(en)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
Antibody molecules that bind to NKP30 and uses thereof
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
WO2020176748A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
|
WO2020185535A1
(en)
|
2019-03-08 |
2020-09-17 |
Genentech, Inc. |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
|
|
EP3938403A1
(en)
|
2019-03-14 |
2022-01-19 |
F. Hoffmann-La Roche AG |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
|
JP7301155B2
(en)
|
2019-04-12 |
2023-06-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Bispecific antigen-binding molecules containing lipocalin muteins
|
|
CN114007643A
(en)
|
2019-04-19 |
2022-02-01 |
中外制药株式会社 |
Chimeric receptors recognizing altered sites of antibodies
|
|
BR112021020867A2
(en)
|
2019-04-19 |
2022-01-04 |
Genentech Inc |
Antibodies, nucleic acid, vector, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, uses of the antibody, method of treating an individual with cancer, and method of reducing clearance
|
|
EP3962523A2
(en)
|
2019-05-03 |
2022-03-09 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
CN114269376A
(en)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
Methods of treating cancer with anti-PD-L1 antibodies
|
|
EP3969035A4
(en)
|
2019-05-14 |
2023-06-21 |
Werewolf Therapeutics, Inc. |
SEPARATION CHARACTERISTIC GROUPS, ASSOCIATED PROCESSES AND USE
|
|
AU2020275415B2
(en)
|
2019-05-14 |
2026-01-15 |
Genentech, Inc. |
Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
|
|
EP4696320A2
(en)
|
2019-05-15 |
2026-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c1s antibody
|
|
WO2020236974A1
(en)
|
2019-05-21 |
2020-11-26 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
|
AU2020278907A1
(en)
|
2019-05-23 |
2022-01-20 |
Ac Immune Sa |
Anti-TDP-43 binding molecules and uses thereof
|
|
KR20220025848A
(en)
|
2019-06-26 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
Fusion of antibodies that bind CEA and 4-1BBL
|
|
WO2020260326A1
(en)
|
2019-06-27 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
|
WO2021003297A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
|
MY208387A
(en)
|
2019-07-09 |
2025-05-05 |
Beijing Solobio Genetechnology Co Ltd |
Antibodies specifically recognizing pseudomonas pcrv and uses thereof
|
|
AR119382A1
(en)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
PRE-TARGETING ANTIBODIES AND METHODS OF USE
|
|
WO2021010326A1
(en)
|
2019-07-12 |
2021-01-21 |
中外製薬株式会社 |
Anti-mutation type fgfr3 antibody and use therefor
|
|
AR119393A1
(en)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
ANTIBODIES THAT BIND NKG2D
|
|
CN114174338A
(en)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
Antibodies that bind to GPRC5D
|
|
CA3248329A1
(en)
|
2019-07-31 |
2025-11-29 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
JP7181438B2
(en)
|
2019-08-06 |
2022-11-30 |
アプリノイア セラピューティクス リミテッド |
Antibodies that bind to pathological tau species and uses thereof
|
|
CN114340675A
(en)
|
2019-09-12 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
Compositions and methods for treating lupus nephritis
|
|
PH12022550646A1
(en)
|
2019-09-18 |
2023-04-03 |
Genentech Inc |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
CA3149719A1
(en)
|
2019-09-19 |
2021-03-25 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
|
CN114423454A
(en)
|
2019-09-20 |
2022-04-29 |
豪夫迈·罗氏有限公司 |
Administration of anti-tryptase antibodies
|
|
JP2022548978A
(en)
|
2019-09-27 |
2022-11-22 |
ジェネンテック， インコーポレイテッド |
Dosing for Treatment with Drugs Anti-TIGIT and Anti-PD-L1 Antagonist Antibodies
|
|
WO2021076196A1
(en)
|
2019-10-18 |
2021-04-22 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
KR20220092580A
(en)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
Diagnosis and treatment methods for the treatment of blood cancer
|
|
US20220396839A1
(en)
|
2019-11-12 |
2022-12-15 |
Foundation Medicine, Inc. |
Methods of detecting a fusion gene encoding a neoantigen
|
|
MX2022005666A
(en)
|
2019-11-14 |
2022-10-07 |
Werewolf Therapeutics Inc |
ACTIVABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF.
|
|
WO2021094620A1
(en)
|
2019-11-15 |
2021-05-20 |
Enthera S.R.L. |
Tmem219 antibodies and therapeutic uses thereof
|
|
US20230039165A1
(en)
|
2019-11-21 |
2023-02-09 |
Enthera S.R.L. |
Igfbp3 antibodies and therapeutic uses thereof
|
|
EP4069742A1
(en)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
|
CN115916817A
(en)
|
2019-12-06 |
2023-04-04 |
朱诺治疗学股份有限公司 |
Anti-idiotypic antibodies directed against BCMA targeting binding domains and related compositions and methods
|
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
KR20220100963A
(en)
|
2019-12-18 |
2022-07-18 |
에프. 호프만-라 로슈 아게 |
Antibodies that bind to HLA-A2/MAGE-A4
|
|
CN113045655A
(en)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
anti-OX 40 antibodies and uses thereof
|
|
UA128549C2
(en)
|
2019-12-27 |
2024-08-07 |
Чугаі Сейяку Кабусікі Кайся |
Anti-ctla-4 antibody and use thereof
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
CN114929734A
(en)
|
2020-01-09 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
Novel antigen binding molecules comprising 4-1BBL trimers
|
|
CN110818795B
(en)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
anti-TIGIT antibodies and methods of use
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
MX2022009391A
(en)
|
2020-01-31 |
2022-09-26 |
Genentech Inc |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine.
|
|
WO2021155295A1
(en)
|
2020-01-31 |
2021-08-05 |
The Cleveland Clinic Foundation |
Anti-müllerian hormone receptor 2 antibodies and methods of use
|
|
TWI895351B
(en)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
Anti-CD137 antigen binding molecules for the treatment of cancer
|
|
TWI890283B
(en)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
|
WO2021168292A1
(en)
|
2020-02-20 |
2021-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Epstein-barr virus monoclonal antibodies and uses thereof
|
|
EP3868396A1
(en)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitors and uses thereof
|
|
KR20220148209A
(en)
|
2020-02-28 |
2022-11-04 |
상하이 헨리우스 바이오테크, 인크. |
Anti-CD137 constructs and uses thereof
|
|
KR20220145859A
(en)
|
2020-02-28 |
2022-10-31 |
상하이 헨리우스 바이오테크, 인크. |
Anti-CD137 constructs, multispecific antibodies and uses thereof
|
|
PE20230252A1
(en)
|
2020-03-13 |
2023-02-07 |
Genentech Inc |
ANTI-INTERLEUKIN-33 ANTIBODIES AND ITS USES FOR THEM
|
|
CN117551194A
(en)
|
2020-03-19 |
2024-02-13 |
基因泰克公司 |
Isotype-selective anti-TGF-β antibodies and methods of use
|
|
CN115867577A
(en)
|
2020-03-23 |
2023-03-28 |
基因泰克公司 |
Biomarkers for predicting response to IL-6 antagonists in COVID-19 pneumonia
|
|
JP2023518815A
(en)
|
2020-03-23 |
2023-05-08 |
ジェネンテック， インコーポレイテッド |
Methods of treating pneumonia, including COVID-19 pneumonia, with an IL6 antagonist
|
|
EP4107186A1
(en)
|
2020-03-23 |
2022-12-28 |
Genentech, Inc. |
Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
|
|
AU2021242249A1
(en)
|
2020-03-24 |
2022-08-18 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
|
JP2023518841A
(en)
|
2020-03-26 |
2023-05-08 |
ジェネンテック， インコーポレイテッド |
Modified mammalian cells with reduced host cell proteins
|
|
AR121706A1
(en)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES
|
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
|
CN115916822A
(en)
|
2020-04-24 |
2023-04-04 |
基因泰克公司 |
Methods of using anti-CD79b immunoconjugates
|
|
JP2023523145A
(en)
|
2020-04-27 |
2023-06-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Isotype-independent antibody against lipoprotein (a)
|
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
TW202200212A
(en)
|
2020-05-03 |
2022-01-01 |
中國大陸商聯寧（蘇州）生物製藥有限公司 |
Antibody-drug conjugates comprising an anti-trop-2 antibody
|
|
EP4157881A4
(en)
|
2020-05-27 |
2024-10-09 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
|
CN116529260A
(en)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
anti-CD 93 constructs and uses thereof
|
|
EP4157462A1
(en)
|
2020-06-02 |
2023-04-05 |
Dynamicure Biotechnology LLC |
Anti-cd93 constructs and uses thereof
|
|
PE20240080A1
(en)
|
2020-06-08 |
2024-01-16 |
Hoffmann La Roche |
ANTI-HBV ANTIBODIES AND METHODS OF USE
|
|
JP2023529206A
(en)
|
2020-06-12 |
2023-07-07 |
ジェネンテック， インコーポレイテッド |
Methods and compositions for cancer immunotherapy
|
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
|
KR20230024368A
(en)
|
2020-06-18 |
2023-02-20 |
제넨테크, 인크. |
Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
WO2021255155A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cd19
|
|
PH12022553489A1
(en)
|
2020-06-19 |
2024-04-22 |
Hoffmann La Roche |
Antibodies binding to cd3 and folr1
|
|
PE20230835A1
(en)
|
2020-06-19 |
2023-05-19 |
Hoffmann La Roche |
ANTIBODIES THAT BIND CD3
|
|
AU2021295549A1
(en)
|
2020-06-23 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic CD28 antigen binding molecules targeting Her2
|
|
CA3184747A1
(en)
|
2020-06-24 |
2021-12-30 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
CN115916830A
(en)
|
2020-06-25 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
Anti-CD3/anti-CD28 bispecific antigen-binding molecules
|
|
CR20230076A
(en)
|
2020-07-10 |
2023-03-13 |
Hoffmann La Roche |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
|
JP7846667B2
(en)
|
2020-07-16 |
2026-04-15 |
レジェンド バイオテック アイルランド リミテッド |
CD20-binding molecules and their use
|
|
PH12023550112A1
(en)
|
2020-07-17 |
2024-06-24 |
Genentech Inc |
Anti-notch2 antibodies and methods of use
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
US20230322935A1
(en)
|
2020-07-29 |
2023-10-12 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
|
JP2023536602A
(en)
|
2020-08-03 |
2023-08-28 |
ジェネンテック， インコーポレイテッド |
Diagnostic and therapeutic methods for lymphoma
|
|
EP4192868A1
(en)
|
2020-08-05 |
2023-06-14 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
|
BR112023002123A2
(en)
|
2020-08-07 |
2023-03-07 |
Genentech Inc |
FC FUSION PROTEIN, ISOLATED NUCLEIC ACIDS, METHOD OF PRODUCING FC FUSION PROTEIN, PHARMACEUTICAL FORMULATION, METHODS FOR EXPANDING THE NUMBER OF DENDRITIC CELLS (DCS) IN AN INDIVIDUAL AND FOR TREATMENT OF CANCER, EFFECTOR-FREE PROTEIN AND ANTI-FCRP
|
|
TW202221026A
(en)
|
2020-08-14 |
2022-06-01 |
瑞士商Ａｃ 免疫有限公司 |
Humanized anti-TDP-43 binding molecules and uses thereof
|
|
WO2022043517A2
(en)
|
2020-08-27 |
2022-03-03 |
Cureab Gmbh |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
|
CA3192344A1
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
|
EP4208201A1
(en)
|
2020-09-04 |
2023-07-12 |
F. Hoffmann-La Roche AG |
Antibody that binds to vegf-a and ang2 and methods of use
|
|
EP4214241A2
(en)
|
2020-09-15 |
2023-07-26 |
Bayer Aktiengesellschaft |
Novel anti-a2ap antibodies and uses thereof
|
|
EP4213877A1
(en)
|
2020-09-17 |
2023-07-26 |
Genentech, Inc. |
Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
|
|
CN118146384A
(en)
|
2020-09-28 |
2024-06-07 |
安济盛生物医药有限公司 |
Anti-sclerostin constructs and uses thereof
|
|
CN116406291A
(en)
|
2020-10-05 |
2023-07-07 |
基因泰克公司 |
Administration of Therapy with Anti-FCRH5/Anti-CD3 Bispecific Antibody
|
|
WO2022084210A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
|
|
AR123855A1
(en)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE
|
|
WO2022084400A1
(en)
|
2020-10-20 |
2022-04-28 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
AU2021374594B2
(en)
|
2020-11-04 |
2026-03-05 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
TWI874719B
(en)
|
2020-11-04 |
2025-03-01 |
美商建南德克公司 |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
JP7716473B2
(en)
|
2020-11-04 |
2025-07-31 |
ジェネンテック， インコーポレイテッド |
Subcutaneous administration of anti-CD20/anti-CD3 bispecific antibodies
|
|
CN117916261A
(en)
|
2020-11-16 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
Combination therapy with FAP-targeted CD40 agonists
|
|
WO2022115865A2
(en)
|
2020-11-25 |
2022-06-02 |
Xilio Development, Inc. |
Tumor-specific cleavable linkers
|
|
WO2022116877A1
(en)
|
2020-12-02 |
2022-06-09 |
Shanghai Henlius Biotech, Inc. |
ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
|
|
TW202237638A
(en)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
|
|
TW202237639A
(en)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
|
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
|
JP2024503826A
(en)
|
2021-01-06 |
2024-01-29 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Combination therapy using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody
|
|
JP2024504931A
(en)
|
2021-01-12 |
2024-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Split antibodies that bind to cancer cells and target radionuclides to said cells
|
|
CA3204291A1
(en)
|
2021-01-13 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Combination therapy
|
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
JP2024504493A
(en)
|
2021-01-28 |
2024-01-31 |
ヴァクスィーンヴェント ゲーエムベーハー |
Methods and means for modulating B cell-mediated immune responses
|
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
|
CN117120084A
(en)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
Methods and means for modulating B cell-mediated immune responses
|
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
AU2022221297A1
(en)
|
2021-02-09 |
2023-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies targeting the spike protein of coronaviruses
|
|
WO2022173689A1
(en)
|
2021-02-09 |
2022-08-18 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
|
KR20230146032A
(en)
|
2021-02-15 |
2023-10-18 |
다케다 야쿠힌 고교 가부시키가이샤 |
Cell therapy compositions and methods for modulating TGF-B signaling
|
|
JP2024512279A
(en)
|
2021-02-26 |
2024-03-19 |
バイエル アクチェンゲゼルシャフト |
Inhibitors of IL-11 or IL-11RA for use in the treatment of abnormal uterine bleeding
|
|
EP4301467A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
|
CA3209364A1
(en)
|
2021-03-01 |
2022-09-09 |
Jennifer O'neil |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
|
US20240181073A1
(en)
|
2021-03-03 |
2024-06-06 |
Sorrento Therapeutics, Inc. |
Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
|
|
TW202302646A
(en)
|
2021-03-05 |
2023-01-16 |
美商當康生物科技有限公司 |
Anti-vista constructs and uses thereof
|
|
WO2022192647A1
(en)
|
2021-03-12 |
2022-09-15 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
AU2022238526A1
(en)
|
2021-03-15 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Compositions and methods of treating lupus nephritis
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
EP4314049A1
(en)
|
2021-03-25 |
2024-02-07 |
Dynamicure Biotechnology LLC |
Anti-igfbp7 constructs and uses thereof
|
|
CN117396504A
(en)
|
2021-03-30 |
2024-01-12 |
拜耳公司 |
anti-Sema 3A antibodies and uses thereof
|
|
AR125344A1
(en)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
ANTI-C1S ANTIBODY
|
|
EP4326855A1
(en)
|
2021-04-19 |
2024-02-28 |
Genentech, Inc. |
Modified mammalian cells
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
IL308351A
(en)
|
2021-05-12 |
2024-01-01 |
Genentech Inc |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
AU2022273303A1
(en)
|
2021-05-14 |
2023-11-02 |
Genentech, Inc. |
Agonists of trem2
|
|
EP4337330A1
(en)
|
2021-05-14 |
2024-03-20 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
CN117396599A
(en)
|
2021-05-21 |
2024-01-12 |
基因泰克公司 |
Modified cells used to produce recombinant products of interest
|
|
AR126009A1
(en)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM
|
|
TW202306994A
(en)
|
2021-06-04 |
2023-02-16 |
日商中外製藥股份有限公司 |
Anti-ddr2 antibodies and uses thereof
|
|
CA3216220A1
(en)
|
2021-06-09 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
|
CN117980333A
(en)
|
2021-06-11 |
2024-05-03 |
基因泰克公司 |
Methods for treating chronic obstructive pulmonary disease using ST2 antagonists
|
|
US12227574B2
(en)
|
2021-06-17 |
2025-02-18 |
Amberstone Biosciences, Inc. |
Anti-CD3 constructs and uses thereof
|
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
US20240279321A1
(en)
|
2021-06-18 |
2024-08-22 |
Therini Bio, Inc. |
ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE
|
|
AR126220A1
(en)
|
2021-06-25 |
2023-09-27 |
Chugai Pharmaceutical Co Ltd |
ANTI-CTLA-4 ANTIBODY
|
|
TWI879694B
(en)
|
2021-06-25 |
2025-04-01 |
日商中外製藥股份有限公司 |
Use of anti-ctla-4 antibodies
|
|
CN118103397A
(en)
|
2021-07-08 |
2024-05-28 |
舒泰神(加州)生物科技有限公司 |
Antibodies that specifically recognize TNFR2 and uses thereof
|
|
EP4370545A1
(en)
|
2021-07-12 |
2024-05-22 |
Genentech, Inc. |
Structures for reducing antibody-lipase binding
|
|
US20240343817A1
(en)
|
2021-07-14 |
2024-10-17 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibody that specifically recognizes cd40 and application thereof
|
|
US12240910B2
(en)
|
2021-07-14 |
2025-03-04 |
Genentech, Inc. |
Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use
|
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
|
CN117794953A
(en)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
Bispecific antibodies and methods of use
|
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
CN117897409A
(en)
|
2021-08-13 |
2024-04-16 |
基因泰克公司 |
Administration of anti-tryptase antibodies
|
|
WO2023021055A1
(en)
|
2021-08-19 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Multivalent anti-variant fc-region antibodies and methods of use
|
|
CA3229448A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
JP2024534151A
(en)
|
2021-08-27 |
2024-09-18 |
ジェネンテック， インコーポレイテッド |
Methods for Treating Tau Pathology
|
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
|
CA3232223A1
(en)
|
2021-09-17 |
2023-03-23 |
Ying Fu |
Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
EP4413998A4
(en)
|
2021-10-08 |
2026-02-25 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR PRODUCING A PRE-FILLED SYRINGE FORMULATION
|
|
US20250251400A1
(en)
|
2021-11-05 |
2025-08-07 |
American Diagnostics & Therapy, Llc (Adxrx) |
Monoclonal Antibodies Against Carcinoembryonic Antigens, and Their Uses
|
|
EP4430072A1
(en)
|
2021-11-10 |
2024-09-18 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
AU2022390134A1
(en)
|
2021-11-16 |
2024-05-16 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
|
TW202337494A
(en)
|
2021-11-16 |
2023-10-01 |
美商建南德克公司 |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
|
EP4437006A1
(en)
|
2021-11-26 |
2024-10-02 |
F. Hoffmann-La Roche AG |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
|
EP4445911A4
(en)
|
2021-12-06 |
2025-10-22 |
Beijing Solobio Genetechnology Co Ltd |
BISPECIFIC ANTIBODY WITH SPECIFIC BINDING TO KLEBSIELLA PNEUMONIAE O2 AND O1 ANTIGENS AND COMPOSITION
|
|
AR127887A1
(en)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
ANTIBODIES THAT BIND CD3 AND PLAP
|
|
KR20240122784A
(en)
|
2021-12-17 |
2024-08-13 |
상하이 헨리우스 바이오테크, 인크. |
Anti-OX40 antibodies and methods of use
|
|
KR20240116755A
(en)
|
2021-12-17 |
2024-07-30 |
상하이 헨리우스 바이오테크, 인크. |
Anti-OX40 antibodies, multispecific antibodies and methods of use thereof
|
|
CR20240246A
(en)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
AGONIST ANTI-LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES THAT INCLUDE THEM
|
|
UY40097A
(en)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
MATERIALS AND METHODS FOR IL-1B BINDING PROTEINS
|
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
|
KR20240142563A
(en)
|
2022-02-10 |
2024-09-30 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Human monoclonal antibodies broadly targeting coronaviruses
|
|
CA3243689A1
(en)
|
2022-02-16 |
2023-08-24 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
|
AU2023221861A1
(en)
|
2022-02-18 |
2024-09-05 |
Rakuten Medical, Inc. |
Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
|
|
EP4489790A1
(en)
|
2022-03-10 |
2025-01-15 |
Vivasor, Inc. |
Antibody-drug conjugates and uses thereof
|
|
MX2024011468A
(en)
|
2022-03-23 |
2024-09-25 |
Hoffmann La Roche |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy.
|
|
CA3245762A1
(en)
|
2022-03-25 |
2023-09-28 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-msln antibodies and methods of use
|
|
US20250197482A1
(en)
|
2022-03-26 |
2025-06-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human |
Bispecific antibodies to hiv-1 env and their use
|
|
EP4499228A1
(en)
|
2022-03-28 |
2025-02-05 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
JP2025511000A
(en)
|
2022-03-28 |
2025-04-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Interferon gamma variants and antigen-binding molecules containing the same
|
|
IL315770A
(en)
|
2022-04-01 |
2024-11-01 |
Genentech Inc |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20260043816A1
(en)
|
2022-04-08 |
2026-02-12 |
Ac Immune Sa |
Anti-TDP-43 Binding Molecules
|
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
US20250257123A1
(en)
|
2022-04-20 |
2025-08-14 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
|
AU2023264069A1
(en)
|
2022-05-03 |
2024-10-24 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
|
CN119487065A
(en)
|
2022-05-09 |
2025-02-18 |
舒泰神（北京）生物制药股份有限公司 |
Antibodies specifically recognizing GDF15 and their applications
|
|
JP2025517650A
(en)
|
2022-05-11 |
2025-06-10 |
ジェネンテック， インコーポレイテッド |
Administration for Treatment with Anti-FcRH5/Anti-CD3 Bispecific Antibody
|
|
AR129268A1
(en)
|
2022-05-11 |
2024-08-07 |
Hoffmann La Roche |
ANTIBODY THAT BINDS TO VEGF-A AND IL6 AND METHODS OF USE
|
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
|
KR20250022049A
(en)
|
2022-06-07 |
2025-02-14 |
제넨테크, 인크. |
Method for determining the efficacy of a treatment for lung cancer comprising an anti-PD-L1 antagonist and an anti-TIGIT antagonist antibody
|
|
US20250382354A1
(en)
|
2022-06-08 |
2025-12-18 |
Institute For Research In Biomedicine (Irb) |
Cross-specific antibodies, uses and methods for discovery thereof
|
|
AU2023305619A1
(en)
|
2022-07-13 |
2025-01-23 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CN120322455A
(en)
|
2022-07-19 |
2025-07-15 |
舒泰神(加州)生物科技有限公司 |
Antibodies specifically recognizing B and T Lymphocyte Attenuators (BTLAs) and uses thereof
|
|
KR20250040020A
(en)
|
2022-07-19 |
2025-03-21 |
제넨테크, 인크. |
Dosage regimen for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
|
|
PE20251075A1
(en)
|
2022-07-22 |
2025-04-10 |
Bristol Myers Squibb Co |
ANTIBODIES THAT BIND TO HUMAN PAD4 AND THEIR USES
|
|
TW202417504A
(en)
|
2022-07-22 |
2024-05-01 |
美商建南德克公司 |
Anti-steap1 antigen-binding molecules and uses thereof
|
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
|
MA71684A
(en)
|
2022-08-05 |
2025-05-30 |
Janssen Biotech, Inc. |
TRANSFERRIN RECEPTOR-BINDING PROTEINS FOR THE TREATMENT OF BRAIN TUMORS
|
|
CA3263779A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
|
EP4577578A1
(en)
|
2022-08-22 |
2025-07-02 |
Abdera Therapeutics Inc. |
Dll3 binding molecules and uses thereof
|
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
|
EP4581366A1
(en)
|
2022-09-01 |
2025-07-09 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
EP4584296A1
(en)
|
2022-09-07 |
2025-07-16 |
Dynamicure Biotechnology LLC |
Anti-vista constructs and uses thereof
|
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
EP4596580A4
(en)
|
2022-09-27 |
2026-01-21 |
Staidson Beijing Biopharmaceuticals Co Ltd |
ANTIBODIES FOR SPECIFIC LIGHT DETECTION AND USE THEM
|
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
|
CN120693395A
(en)
|
2022-10-20 |
2025-09-23 |
北京三诺佳邑生物技术有限责任公司 |
Antibody combinations and bispecific antibodies that specifically bind to TRAIL or FasL
|
|
KR20250093336A
(en)
|
2022-10-25 |
2025-06-24 |
제넨테크, 인크. |
Treatment and Diagnosis Methods for Multiple Myeloma
|
|
JP2025537137A
(en)
|
2022-11-04 |
2025-11-14 |
ギリアード サイエンシーズ， インコーポレイテッド |
Anti-cancer therapy using a combination of anti-CCR8 antibodies, chemotherapy and immunotherapy
|
|
EP4615872A1
(en)
|
2022-11-08 |
2025-09-17 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
|
EP4615580A1
(en)
|
2022-11-09 |
2025-09-17 |
CIS Biopharma AG |
Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
EP4619045A1
(en)
|
2022-11-17 |
2025-09-24 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
|
JPWO2024111657A1
(en)
|
2022-11-25 |
2024-05-30 |
|
|
|
EP4588936A1
(en)
|
2022-12-08 |
2025-07-23 |
Changchun Bcht Biotechnology Co. |
Antibodies specifically binding to rsv
|
|
WO2024137381A1
(en)
|
2022-12-19 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies for treating sars-cov-2 infection
|
|
JP2026510546A
(en)
|
2023-01-18 |
2026-04-08 |
ジェネンテック， インコーポレイテッド |
Multispecific antibodies and their use
|
|
CN120569410A
(en)
|
2023-01-25 |
2025-08-29 |
豪夫迈·罗氏有限公司 |
Antibodies that bind to CSF1R and CD3
|
|
AU2024221322A1
(en)
|
2023-02-17 |
2025-07-03 |
Apogee Therapeutics, Inc. |
Antibodies that bind interleukin 4 receptor alpha and methods of use
|
|
EP4676596A1
(en)
|
2023-03-08 |
2026-01-14 |
AC Immune SA |
Anti-tdp-43 binding molecules and uses thereof
|
|
JP2026509243A
(en)
|
2023-03-10 |
2026-03-17 |
ジェネンテック， インコーポレイテッド |
Fusion with proteases and their use
|
|
EP4428158A1
(en)
|
2023-03-10 |
2024-09-11 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Lung cancer targeting human antibodies and therapeutic uses thereof
|
|
EP4428159A1
(en)
|
2023-03-10 |
2024-09-11 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Melanoma targeting human antibodies and therapeutic uses thereof
|
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
|
CN120936626A
(en)
|
2023-03-31 |
2025-11-11 |
基因泰克公司 |
Anti-αvβ8 integrin antibody and its usage
|
|
CN121969397A
(en)
|
2023-04-05 |
2026-05-01 |
维硕公司 |
Antibody-conjugated drugs and uses thereof
|
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
CN121969398A
(en)
|
2023-04-05 |
2026-05-01 |
维硕公司 |
Antibody-drug conjugates and their uses
|
|
CN121263432A
(en)
|
2023-04-12 |
2026-01-02 |
上海康抗生物技术有限公司 |
Multifunctional molecules comprising masked interleukin 12 and methods of use
|
|
KR20260012304A
(en)
|
2023-04-17 |
2026-01-26 |
피크 바이오, 인크. |
Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
|
|
AU2024270495A1
(en)
|
2023-05-05 |
2025-10-09 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
EP4709752A1
(en)
|
2023-05-08 |
2026-03-18 |
F. Hoffmann-La Roche AG |
Targeted interferon alpha fusion proteins and methods of use
|
|
EP4709484A1
(en)
|
2023-05-10 |
2026-03-18 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
AU2024273454A1
(en)
|
2023-05-16 |
2025-11-27 |
F. Hoffmann-La Roche Ag |
Pd-1-regulated il-2 immunocytokine and uses thereof
|
|
WO2024243355A1
(en)
|
2023-05-24 |
2024-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
|
|
WO2024246083A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies targeting bcma and cd28
|
|
TW202502811A
(en)
|
2023-06-01 |
2025-01-16 |
瑞士商赫孚孟拉羅股份公司 |
Immunostimulatory antigen binding molecules that specifically bind to bcma
|
|
KR20260021689A
(en)
|
2023-06-08 |
2026-02-13 |
제넨테크, 인크. |
Macrophage Signatures for Lymphoma Diagnosis and Treatment
|
|
CN121311247A
(en)
|
2023-06-09 |
2026-01-09 |
舒泰神（北京）生物制药股份有限公司 |
Antibodies that specifically bind to MASP3 and multispecific antibodies that specifically bind to both MASP3 and MASP2
|
|
CN121358781A
(en)
|
2023-06-16 |
2026-01-16 |
江苏贝捷泰生物科技有限公司 |
Antibodies that specifically recognize factor XIIa and their applications
|
|
KR20260026086A
(en)
|
2023-06-21 |
2026-02-25 |
에프. 호프만-라 로슈 아게 |
Combination therapy with FAP-targeting lymphotoxin beta receptor agonists
|
|
EP4731255A1
(en)
|
2023-06-22 |
2026-04-29 |
Genentech, Inc. |
Treatment of multiple myeloma
|
|
EP4731668A1
(en)
|
2023-06-22 |
2026-04-29 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
KR20260041867A
(en)
|
2023-07-21 |
2026-03-27 |
브리스톨-마이어스 스큅 컴퍼니 |
Method for evaluating the citrullination and activity of PAD4 modifiers
|
|
AU2024300009A1
(en)
|
2023-07-21 |
2026-01-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies that broadly target coronaviruses
|
|
WO2025021790A2
(en)
|
2023-07-24 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
AU2024300993A1
(en)
|
2023-07-26 |
2026-01-22 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
WO2025032069A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
KR20260051042A
(en)
|
2023-08-09 |
2026-04-15 |
에프. 호프만-라 로슈 아게 |
Single and multispecific anti-TREM2 antibodies, methods and uses thereof
|
|
CN121620524A
(en)
|
2023-08-09 |
2026-03-06 |
豪夫迈·罗氏有限公司 |
Anti-A-β protein antibodies, methods and applications
|
|
AU2024324215A1
(en)
|
2023-08-11 |
2026-02-26 |
Abalytics Oncology, Inc. |
Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025045251A2
(en)
|
2023-09-03 |
2025-03-06 |
Kira Pharmaceuticals (Us) Llc |
Multispecific constructs comprising anti-factor d moiety
|
|
WO2025064539A1
(en)
|
2023-09-19 |
2025-03-27 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Herv-e antibodies and methods of their use
|
|
AR133909A1
(en)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTIBODY THAT BINDS TO C3bBb
|
|
EP4537907A1
(en)
|
2023-10-10 |
2025-04-16 |
Enthera S.r.l. |
Cd248 inhibitors and uses thereof
|
|
WO2025085489A1
(en)
|
2023-10-17 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
|
|
TW202517674A
(en)
|
2023-10-19 |
2025-05-01 |
德商拜耳廠股份有限公司 |
Anti-gpc3 antibodies and radioconjugates thereof
|
|
WO2025099120A1
(en)
|
2023-11-09 |
2025-05-15 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies with conditional activity
|
|
WO2025106427A1
(en)
|
2023-11-14 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2025111402A1
(en)
|
2023-11-21 |
2025-05-30 |
Board Of Regents Of The University Of Nebraska |
Anti-amyloid beta antibodies and related compositions and methods thereof
|
|
WO2025117384A1
(en)
|
2023-12-01 |
2025-06-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
|
|
WO2025125118A1
(en)
|
2023-12-11 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
TW202535949A
(en)
|
2023-12-20 |
2025-09-16 |
美商必治妥美雅史谷比公司 |
Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
|
|
WO2025137410A1
(en)
|
2023-12-20 |
2025-06-26 |
Apogee Therapeutics, Inc. |
Pharmaceutical compositions of anti-il-13 antibodies with and without c-terminal lysine
|
|
WO2025137523A2
(en)
|
2023-12-20 |
2025-06-26 |
Apogee Therapeutics, Inc. |
Pharmaceutical formulations of antibodies that bind interleukin 13
|
|
WO2025132503A1
(en)
|
2023-12-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to ceacam5
|
|
WO2025137284A2
(en)
|
2023-12-21 |
2025-06-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants
|
|
WO2025133290A1
(en)
|
2023-12-21 |
2025-06-26 |
Temper Bio |
Protein for immune regulation
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
WO2025174974A1
(en)
|
2024-02-14 |
2025-08-21 |
Bristol-Myers Squibb Company |
Anti-cd33 antibodies and uses thereof
|
|
WO2025179281A1
(en)
|
2024-02-23 |
2025-08-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of cardiovascular disease with antxr1 antibodies
|
|
WO2025184416A1
(en)
|
2024-02-27 |
2025-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single-domain antibodies and bispecific antibodies against hiv-1 and their use
|
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025199352A2
(en)
|
2024-03-20 |
2025-09-25 |
Juno Therapeutics, Inc. |
Antibodies specific for solute carrier family 34 member 2 (slc34a2)
|
|
WO2025196639A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody-drug conjugates, and uses thereof
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025226808A1
(en)
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025238187A1
(en)
|
2024-05-15 |
2025-11-20 |
Cis Biopharma Ag |
Immunoconjugates targeting l1-cam
|
|
WO2025242909A1
(en)
|
2024-05-24 |
2025-11-27 |
Paul Scherrer Institut |
CD30-targeting antibody-radioligand conjugates and their therapeutic use
|
|
WO2025250969A1
(en)
|
2024-05-31 |
2025-12-04 |
Vertex Pharmaceuticals Incorporated |
Anti-cd74 antibodies, conjugates and uses thereof
|
|
WO2025255353A1
(en)
|
2024-06-06 |
2025-12-11 |
Apogee Therapeutics, Inc. |
Dosage and administration of an anti-ox40l antibody
|
|
WO2025262564A1
(en)
|
2024-06-17 |
2025-12-26 |
Pfizer Inc. |
Use of anti-cxcr5 antibodies
|
|
WO2025264972A1
(en)
|
2024-06-21 |
2025-12-26 |
Apogee Therapeutics, Inc. |
Antibodies that bind il-4r alpha and antibodies that bind
|
|
WO2025264960A1
(en)
|
2024-06-21 |
2025-12-26 |
Apogee Therapeutics, Inc. |
Antibodies that bind il-13 and antibodies that bind ox40l
|
|
WO2026013218A1
(en)
|
2024-07-10 |
2026-01-15 |
Ac Immune Sa |
Anti-tdp-43 vectors, binding molecules and uses thereof
|
|
EP4684803A1
(en)
|
2024-07-25 |
2026-01-28 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Antibody conjugated chemical inducers of degradation of rbm39 and therapeutic uses thereof
|
|
WO2026030464A1
(en)
|
2024-07-30 |
2026-02-05 |
Genentech, Inc. |
Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
|
|
WO2026030473A1
(en)
|
2024-07-31 |
2026-02-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
West nile virus neutralizing monoclonal antibodies
|
|
WO2026041568A1
(en)
|
2024-08-20 |
2026-02-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and dotam
|
|
WO2026050244A1
(en)
|
2024-08-26 |
2026-03-05 |
Angitia Incorporated Limited |
Methods of treating or preventing osteoporosis and low bone mass
|
|
WO2026072685A1
(en)
|
2024-09-25 |
2026-04-02 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2026073840A1
(en)
|
2024-10-01 |
2026-04-09 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to cd3 and uses therefor
|
|
WO2026080829A1
(en)
|
2024-10-10 |
2026-04-16 |
Apogee Therapeutics, Inc. |
Methods of administering antibodies that bind interleukin 13
|
|
EP4729541A1
(en)
|
2024-10-16 |
2026-04-22 |
Paolo Fiorina |
Anti- igfbp7 antibodies and uses thereof
|
|
WO2026085414A1
(en)
|
2024-10-18 |
2026-04-23 |
Apogee Therapeutics, Inc. |
Antibodies that bind tslp and antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
|
|
WO2026085415A1
(en)
|
2024-10-18 |
2026-04-23 |
Apogee Therapeutics, Inc. |
Antibodies that bind il-13 and antibodies that bind tslp in combination with hyaluronidase or a variant thereof
|
|
WO2026085419A2
(en)
|
2024-10-18 |
2026-04-23 |
Apogee Therapeutics, Inc. |
Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof
|
|
WO2026085417A2
(en)
|
2024-10-18 |
2026-04-23 |
Apogee Therapeutics, Inc. |
Antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
|